Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia
- 10 March 2005
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 19 (5) , 750-758
- https://doi.org/10.1038/sj.leu.2403707
Abstract
Prognostic predictions in B-cell chronic lymphocytic leukemia (B-CLL) at early clinical stage are based on biological disease parameters, such as ZAP-70 and CD38 protein levels, genomic aberrations as well as immunoglobulin variable heavy chain gene (IgVH) mutation status. In the current study, ZAP-70 and CD38 expressions were examined by flow cytometry in 252 patients with B-CLL. Cytoplasmic ZAP-70 expression in more than 20% (ZAP-70+) and surface CD38 expression on more than 30% (CD38+) of B-CLL cells were associated with an unfavorable clinical course. The levels of ZAP-70 and CD38 did not change over time in the majority of patients where sequential samples were available for analysis. Combined analysis of ZAP-70 and CD38 yielded discordant results in 73 patients (29.0%), whereas 120 patients (47.6%) were concordantly negative and 59 patients (23.4%) were concordantly positive for ZAP-70 and CD38 expression. Median treatment-free survival times in patients whose leukemic cells were ZAP-70+CD38+ was 30 months as compared to 130 months in patients with a ZAP-70-CD38- status. In patients with discordant ZAP-70/CD38 results, the median treatment-free survival time was 43 months. Thus, ZAP-70 and CD38 expression analyses provided complementary prognostic information identifying three patient subgroups with good, intermediate and poor prognosis. Over-representation of high-risk genomic aberrations such as 17p deletion or 11q deletion and distribution of the IgVH mutation status in B-CLL discordant for ZAP-70/CD38 pointed toward a distinct biologic background of the observed disease subgroups. This finding was also supported by microarray-based gene expression profiling in a subset of 35 patients. The expression of 37 genes differed significantly between the three groups defined by their expression of ZAP-70 and CD38, including genes that are involved in regulation of cell survival and chemotherapy resistance.Keywords
This publication has 33 references indexed in Scilit:
- CD38 modifications in chronic lymphocytic leukemia: are they relevant?Leukemia, 2004
- Routine Analysis of IgVHMutational Status in CLL Patients using BIOMED-2 Standardized Primers and ProtocolsLeukemia & Lymphoma, 2004
- B-cell Chronic Lymphocytic Leukemia with Aberrant CD8 Expression: Genetic and Immunophenotypic Analysis of Prognostic FactorsLeukemia & Lymphoma, 2004
- Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLLBlood, 2004
- ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileBlood, 2003
- The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progressionBlood, 2003
- CD38 expression is an important prognostic marker in chronic lymphocytic leukaemiaLeukemia, 2002
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic LeukemiaThe Journal of Experimental Medicine, 2001
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working groupAmerican Journal of Hematology, 1988